This site is intended for healthcare professionals
News

Altamira Therapeutics receives FDA 510(k) clearance for Bentrio to treat allergic rhinitis.

Read time: 1 mins
Published:28th Jun 2022

Altamira Therapeutics Ltd. announced that the Company's US subsidiary has received 510(k) clearance from the FDA to market its nasal spray Bentrio ("Bentrio Allergy Blocker") for the treatment of allergic rhinitis (hay fever).

 

Clearance was provided for the following indication for use: "Bentrio is intended to treat hay fever and allergy sufferers by promoting alleviation of mild allergic symptoms (i.e. mild nasal irritation including itchy, runny, or congested nasal passages) triggered by the inhalation of various airborne allergens including indoor and outdoor environmental pollens, house dust, animal hair and dust mites. Application of Bentrio produces a mucous-like gel barrier that coats the nasal membranes, traps inhaled allergens within the nasal cavity and helps with their clearance."

Condition: Allergic Rhinitis
Type: drug

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.